A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
Details
Age
Adult
Locations
Memorial Hospital Central
Memorial Hospital North
Principal Investigator
Robert Hoyer
Study ID
Protocol Number: 23-1996
More information available at ClinicalTrials.gov: NCT06077760
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers